GlassScriptPhysician profile
Paula Salas
NPI 1558528026
$3,783.63
in general payments reported to CMS, 2019-2025
32 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $423 · 2021: $284 · 2022: $686 · 2023: $588 · 2024: $76.93 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,008.54 | 2019-2025 | Fasenra, Tezspire, Imfinzi |
| Novo Nordisk INC | $718.23 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $567.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $262.17 | 2019-2025 | Trelegy Ellipta, Pediarix, Bexsero |
| Fisher & Paykel Healthcare INC | $149.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $140.20 | 2019-2023 | |
| Edwards Lifesciences Corporation | $131.41 | 2021 | |
| Sanofi-Aventis U.S. LLC | $131.25 | 2019-2023 | |
| Insmed, INC. | $120.65 | 2019 | |
| Dexcom, INC. | $62.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.45 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $52.05 | 2019 | |
| Dynavax Technologies Corporation | $34.29 | 2023 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $34.12 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.65 | 2022-2023 | Eliquis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $23.52 | 2022 | |
| Amarin Pharma, INC. | $23.03 | 2022 | |
| Abbvie INC. | $22.67 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $20.71 | 2025 | Opsumit, Uptravi |
| Allergan, INC. | $18.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.66 | 2019 | |
| Exact Sciences Corporation | $18.15 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $18.10 | 2023 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $15.85 | 2023 | Quviviq |
| Roche Diagnostics Corporation | $15.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $14.72 | 2019 | |
| Corcept Therapeutics | $14.20 | 2021 | |
| Endo Pharmaceuticals INC. | $13.76 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.25 | 2019 | |
| Lilly USA, LLC | $11.54 | 2019 | |
| Merck Sharp & Dohme LLC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Salas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.